Novel therapy to reverse the cellular effects of bisphosphonates on primary human oral fibroblasts

Journal of Oral and Maxillofacial Surgery

Volumn 69, Issue 10, 2011, Pages 2564-2578

  Cozin, Matthew ^a   Pinker, Bradley M ^a   Solemani, Kimberley ^a   Zuniga, Jeremy M ^a   Dadaian, Stephen C ^a   Cremers, Serge ^a   Landesberg, Regina ^b   Raghavan, Srikala ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

F ACTIN; GERANYLGERANIOL; PAMIDRONIC ACID; RECOMBINANT PLATELET DERIVED GROWTH FACTOR BB; ZOLEDRONIC ACID;

APOPTOSIS; ARTICLE; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ANTAGONISM; FIBROBLAST; GINGIVA; HUMAN; HUMAN CELL; JAW OSTEONECROSIS; NICK END LABELING;

EID: 80053051680     PISSN: 02782391     EISSN: 15315053     Source Type: Journal    
DOI: 10.1016/j.joms.2011.03.005     Document Type: Article

References (61)

1. G. Colella, G. Campisi, and V. Fusco American Association of Oral and Maxillofacial Surgeons position paper: Bisphosphonate-related osteonecrosis of the jaws2009 update: The need to refine the BRONJ definition J Oral Maxillofac Surg 12 2009 2698
2. S. Khosla, D. Burr, and J. Cauley Bisphosphonate-associated osteonecrosis of the jaw: Report of a task force of the American Society for Bone and Mineral Research J Bone Miner Res 10 2007 1479
3. R.A. Kyle, G.C. Yee, and M.R. Somerfield; American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma J Clin Oncol 17 2007 2464
4. V. Patel, N.M. McLeod, and S.N. Rogers Bisphosphonate osteonecrosis of the jawA literature review of UK policies versus international policies on bisphosphonates, risk factors and prevention Br J Oral Maxillofac Surg 49 2011 335
5. S.L. Ruggiero, T.B. Dodson, and L.A. Assael American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws2009 update J Oral Maxillofac Surg 5 suppl 2009 2
6. S.L. Ruggiero, J. Fantasia, and E. Carlson Bisphosphonate-related osteonecrosis of the jaw: Background and guidelines for diagnosis, staging and management Oral Surg Oral Med Oral Pathol Oral Radiol Endod 4 2006 433
7. T. Yoneda, H. Hagino, and T. Sugimoto Bisphosphonate-related osteonecrosis of the jaw: Position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology, and Japanese Society of Oral and Maxillofacial Surgeons J Bone Miner Metab 4 2010 365
8. T.B. Dodson Intravenous bisphosphonate therapy and bisphosphonate-related osteonecrosis of the jaws J Oral Maxillofac Surg 5 suppl 2009 44
9. M. Kos, J.F. Kuebler, and K. Luczak Bisphosphonate-related osteonecrosis of the jaws: A review of 34 cases and evaluation of risk J Craniomaxillofac Surg 4 2010 255
10. V. Thumbigere-Math, M.C. Sabino, and R. Gopalakrishnan Bisphosphonate-related osteonecrosis of the jaw: Clinical features, risk factors, management, and treatment outcomes of 26 patients J Oral Maxillofac Surg 9 2009 1904
11. E.P. Wang, L.B. Kaban, and G.J. Strewler Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy J Oral Maxillofac Surg 7 2007 1328
12. R. Landesberg, M. Cozin, and S. Cremers Inhibition of oral mucosal cell wound healing by bisphosphonates J Oral Maxillofac Surg 5 2008 839
13. H. Agis, J. Blei, and G. Watzek Is zoledronate toxic to human periodontal fibroblasts? J Dent Res 1 2010 40
14. F. Correia Vde, C.L. Caldeira, and M.M. Marques Cytotoxicity evaluation of sodium alendronate on cultured human periodontal ligament fibroblasts Dent Traumatol 6 2006 312
15. M.J. Ravosa, J. Ning, and Y. Liu Bisphosphonate effects on the behaviour of oral epithelial cells and oral fibroblasts Arch Oral Biol 56 2011 5
16. M.A. Scheper, A. Badros, and R. Chaisuparat Effect of zoledronic acid on oral fibroblasts and epithelial cells: A potential mechanism of bisphosphonate-associated osteonecrosis Br J Haematol 5 2009 667
17. C. Walter, M.O. Klein, and A. Pabst Influence of bisphosphonates on endothelial cells, fibroblasts, and osteogenic cells Clin Oral Investig 1 2010 35
18. F.P. Coxon, K. Thompson, and M.J. Rogers Recent advances in understanding the mechanism of action of bisphosphonates Curr Opin Pharmacol 3 2006 307
19. J. Green, and A. Lipton Anticancer properties of zoledronic acid Cancer Invest 9 2010 944
20. B.E. Hillner, and J.N.Berenson Ingle American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer American Society of Clinical Oncology Bisphosphonates Expert Panel J Clin Oncol 6 2000 1378
21. L.S. Rosen, D. Gordon, and M. Kaminski Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial Cancer J 5 2001 377
22. F. Saad, D.M. Gleason, and R. Murray A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma J Natl Cancer Inst 19 2002 1458
23. D. Santini, B. Vincenzi, and G. Avvisati Pamidronate induces modifications of circulating angiogenetic factors in cancer patients Clin Cancer Res 5 2002 1080
24. D. Santini, B. Vincenzi, and G. Dicuonzo Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients Clin Cancer Res 8 2003 2893
25. T. Usui, Y. Oiso, and A. Tomita Pharmacokinetics of incadronate, a new bisphosphonate, in healthy volunteers and patients with malignancy-associated hypercalcemia Int J Clin Pharmacol Ther 6 1997 239
26. C.H. Van Poznak The use of bisphosphonates in patients with breast cancer Cancer Control 6 2002 480
27. B. Vincenzi, D. Santini, and G. Dicuonzo Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients J Interferon Cytokine Res 3 2005 144
28. P. Major The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy Oncologist 6 2002 481
29. J.D. Bergstrom, R.G. Bostedor, and P.J. Masarachia Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase Arch Biochem Biophys 1 2000 231
30. F.P. Coxon, and M.J. Rogers The role of prenylated small GTP-binding proteins in the regulation of osteoclast function Calcif Tissue Int 1 2003 80
31. M. Goffinet, M. Thoulouzan, and A. Pradines Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells BMC Cancer 6 2006 60
32. M. Nogawa, T. Yuasa, and S. Kimura Zoledronic acid mediates Ras-independent growth inhibition of prostate cancer cells Oncol Res 1 2005 1
33. K. Suyama, Y. Noguchi, and T. Tanaka Isoprenoid-independent pathway is involved in apoptosis induced by risedronate, a bisphosphonate, in which Bim plays a critical role in breast cancer cell line MCF-7 Oncol Rep 5 2007 1291
34. W.B. Zhong, Y.C. Liang, and C.Y. Wang Lovastatin suppresses invasiveness of anaplastic thyroid cancer cells by inhibiting Rho geranylgeranylation and RhoA/ROCK signaling Endocr Relat Cancer 3 2005 615
35. J.L. Goldstein, and M.S. Brown Regulation of the mevalonate pathway Nature 6257 1990 425
36. D.L. Steed Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers Diabetic Ulcer Study Group J Vasc Surg 1 1995 71
37. J.L. Wallace, M. Dicay, and W. McKnight N-bisphosphonates cause gastric epithelial injury independent of effects on the microcirculation Aliment Pharmacol Ther 12 1999 1675
38. R.E. Marx Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic J Oral Maxillofac Surg 9 2003 1115
39. A. Kyrgidis, K. Vahtsevanos, and G. Koloutsos Bisphosphonate-related osteonecrosis of the jaws: A case-control study of risk factors in breast cancer patients J Clin Oncol 28 2008 4634
40. A.O. Hoff, B.B. Toth, and K. Altundag The frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates J Bone Miner Res 23 2008 826
41. R. Landesberg, V. Woo, and S. Cremers Potential pathophysiological mechanisms in osteonecrosis of the jaw Ann N Y Acad Sci 1 2011 62
42. M.H. Amler The time sequence of tissue regeneration in human extraction wounds Oral Surg Oral Med Oral Pathol 3 1969 309
43. E.S. Elsubeihi, and J.N. Heersche Quantitative assessment of post-extraction healing and alveolar ridge remodelling of the mandible in female rats Arch Oral Biol 5 2004 401
44. I.R. Reid, M.J. Bolland, and A.B. Grey Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone 3 2007 318
45. B. Mehrotra BisphosphonatesRole in cancer therapies J Oral Maxillofac Surg 5 suppl 2009 19
46. D.E. Hughes, K.R. Wright, and H.L. Uy Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo J Bone Miner Res 10 1995 1478
47. E. Giraudo, M. Inoue, and D. Hanahan An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis J Clin Invest 5 2004 623
48. S. Suri, J. Monkkonen, and M. Taskinen Nitrogen-containing bisphosphonates induce apoptosis of Caco-2 cells in vitro by inhibiting the mevalonate pathway: A model of bisphosphonate-induced gastrointestinal toxicity Bone 4 2001 336
49. I.M. Twiss, R. de Water, and J. den Hartigh Cytotoxic effects of pamidronate on monolayers of human intestinal epithelial (Caco-2) cells and its epithelial transport J Pharm Sci 5 1994 699
50. I.M. Twiss, O. Pas, and W. Ramp-Koopmanschap The effects of nitrogen-containing bisphosphonates on human epithelial (Caco-2) cells, an in vitro model for intestinal epithelium J Bone Miner Res 5 1999 784
51. P.C. de Groen, D.F. Lubbe, and L.J. Hirsch Esophagitis associated with the use of alendronate N Engl J Med 14 1996 1016
52. J.O. Hollinger, C.E. Hart, S.N. Hirsch, S. Lynch, and G.E. Friedlaender Recombinant human platelet-derived growth factor: Biology and clinical applications J Bone Joint Surg Am 90 suppl 1 2008 48
53. G. Pellegrini, Y.J. Seol, and R. Gruber Pre-clinical models for oral and periodontal reconstructive therapies J Dent Res 12 2009 1065
54. C.S. Young, C.F. Ladd, and Browning Release, biological potency, and biochemical integrity of recombinant human platelet-derived growth factor-BB (rhPDGF-BB) combined with Augment(TM) Bone Graft or GEM 21S beta-tricalcium phosphate (beta-TCP) J Control Release 3 2009 250
55. E.R. Van Beek, C.W. Lowik, and S.E. Papapoulos Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: The role of protein geranylgeranylation in the action of nitrogen-containing bisphosphonates on osteoclast precursors Bone 1 2002 64
56. J.C. Frith, J. Monkkonen, and G.M. Blackburn Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5′-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro J Bone Miner Res 9 1997 1358
57. M. Hasmim, G. Bieler, and C. Ruegg Zoledronate inhibits endothelial cell adhesion, migration and survival through the suppression of multiple, prenylation-dependent signaling pathways J Thromb Haemost 1 2007 166
58. S. Raghavan, A. Vaezi, and E. Fuchs A role for alphabeta1 integrins in focal adhesion function and polarized cytoskeletal dynamics Dev Cell 3 2003 415
59. A.J. Ridley Rho GTPases and actin dynamics in membrane protrusions and vesicle trafficking Trends Cell Biol 10 2006 522
60. F.G. Giancotti, and E. Ruoslahti Integrin signaling Science 5430 1999 1028
61. E. Zamir, and B. Geiger Molecular complexity and dynamics of cell-matrix adhesions J Cell Sci 114 pt 20 2001 3583